Journal Watch · Journal of Medicinal Chemistry · 2026
Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL<sup>Pro</sup>.
This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.
TL;DR
This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.
Key findings
- This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.
What they did
Here, we describe the discovery of potent PL<sup>Pro</sup> inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes. Lead compound <b>46</b> is shown to bind to the S3 and S4 pockets with nanomolar affinity (0.4 μM) and exhibits robust cellular activity and resistance to mutation.
Full abstract (original)
Background: SARS-CoV-2 papain-like protease (PL<sup>Pro</sup>) plays a key role in viral replication and the host immune response and is a promising target for developing new antiviral treatments. We previously reported a fragment-based screen to identify hits that bind to SARS-CoV-2 PL<sup>Pro</sup>.
What they did: Here, we describe the discovery of potent PL<sup>Pro</sup> inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes. Lead compound <b>46</b> is shown to bind to the S3 and S4 pockets with nanomolar affinity (0.4 μM) and exhibits robust cellular activity and resistance to mutation.
Results & conclusions: This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02832 · PubMed 41521555.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
This novel class of PL<sup>Pro</sup> inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks.
What type of study is this?
It is a research study, published in Journal of Medicinal Chemistry in 2026. Here, we describe the discovery of potent PL<sup>Pro</sup> inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02832. PubMed ID: 41521555. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-of-fragment-based-inhibitors-of-sars-cov-2-pl-lt-sup-gt-pro-lt-c02832/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides